Chantal Sauvageau completed her Doctorate in Medicine at Laval University in 1999, and obtained a Master’s degree in Community Health from the same University in 2002. She then completed her specialty training and obtained her certificate of specialist in Community Health from the Collège des médecins du Québec and the Royal College of Physicians and Surgeons of Canada, in 2004. She is a consultant in infectious diseases at the National Institute of Public Health of Quebec, and the Regional Directorate of Public Health of the national capital. She is a researcher in the Immunization Research Team of the Research Centre of the CHU de Québec, and an Associate Professor in the Faculty of Medicine at Laval University. She has been an active member of the Committee on Immunization of Quebec (CIQ) since 2008. She is also a member of the shingles working group as well as of the HPV working group of the National Advisory Committee on Immunization (NACI). In 2013, she participated in the work of the World Health Organization (WHO), leading to a WHO recommendation on the use of a 2-dose vaccination schedule for HPV vaccine.

Evaluate the impact of HPV vaccination and the vaccination against chickenpox and shingles

Her main research papers focus on HPV vaccination, particularly on the evaluation of the immunogenicity and efficacy of available vaccines, on the impact of varicella and shingles vaccination, on the training of healthcare professionals on immunization, and the problem of vaccine delays. More specifically, by conducting clinical trials, her projects aim to know the immune response to vaccines: duration of protection, decrease in antibody levels, impact of interactions and co-administration of vaccines on the immune response, effect of a booster dose, etc. Among other things, she is the co-principal investigator of a randomized clinical trial named ICI-HPV, having recruited 3,300 14-16 year old girls from 2013 to 2016, who are followed for 5 years. The trial aims to evaluate the effectiveness of a 2-dose schedule of HPV vaccination, 10 years after receiving the first dose of vaccine at an age of 9 or 10.

She also collaborates on projects related to the modeling and analysis of the cost-effectiveness of planned or implemented vaccination programs, as well as on studies related to the acceptability of implemented vaccination programs, by measuring the immunization coverage rate, as well as the perception of health professionals and of the population.

2400, avenue d'Estimauville
3e étage
U-3130
Québec, Québec
Canada G1E 7G9
+1 418-650-5115, extension 6368+1 418-666-2776
chantal.sauvageau@crchude... chantal.sauvageau@inspq.q...

Latest news

157 entries « ‹ 1 of 16 › »

Dionne M, Sauvageau C, Etienne D, Kiely M, Witteman H, Dubé E

Development of Promising Interventions to Improve Human Papillomavirus Vaccination in a School-Based Program in Quebec, Canada: Results From a Formative Evaluation Using a Mixed Methods Design

Journal Article

JMIR Form Res, 8 , 2024.

Abstract | Links:

Alessandrini J, Cox J, de Pokomandy A, Hart TA, Grace D, Grennan T, Moore D, Lambert G, Chambers C, Deeks SL, Grewal R, Lachowsky NJ, Sauvageau C, Tan DHS, Coutlée F, Burchell AN

Prevalence of Oral Human Papillomavirus Infection Among Urban Gay, Bisexual, and Other Men Who Have Sex With Men in Canada, 2017-2019

Journal Article

J Infect Dis, 2024.

Abstract | Links:

Razafimandimby H, Sauvageau C, Ouakki M, Carazo S, Skowronski DM, De Serres G

Effectiveness of BNT162b2 Vaccine Against Omicron-SARS-CoV-2 Subvariants in Children 5-11 Years of Age in Quebec, Canada, January 2022 to January 2023

Journal Article

Pediatr Infect Dis J, 43 (1), 2024.

Abstract | Links:

Dionne M, Sauvageau C, Kiely M, Dahhou M, Hamel D, Rathwell M, Bandara T, Neudorf C, Dubé È

School-based vaccination program against HPV and Hepatitis B: A longitudinal analysis of vaccine coverage between 2015 and 2021 in Quebec

Journal Article

Vaccine, 42 (1), 2024.

Abstract | Links:

Dionne M, Étienne D, Witteman HO, Sauvageau C, Dubé È

Impact of interventions to improve HPV vaccination acceptance and uptake in school-based programs: Findings of a pilot project in Quebec

Journal Article

Vaccine, 42 (18), 2024.

Abstract | Links:

Grewal R, Deeks SL, Hart TA, Cox J, De Pokomandy A, Grennan T, Lambert G, Moore D, Gaspar M, George C, Gillis J, Grace D, Jollimore J, Lachowsky NJ, Nisenbaum R, Ogilvie G, Sauvageau C, Tan DH, Yeung AN, Burchell AN

HPV vaccination among gay, bisexual and other men who have sex with men in Canada's three largest cities: a person-centred approach

Journal Article

JOURNAL OF MENS HEALTH, 19 (10), 2023.

Abstract | Links:

Carazo S, Skowronski DM, Brisson M, Barkati S, Sauvageau C, Brousseau N, Gilca R, Fafard J, Talbot D, Ouakki M, Gilca V, Carignan A, Deceuninck G, De Wals P, De Serres G

Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study

Journal Article

Lancet Infect Dis, 23 (1), 2023.

Abstract | Links:

Ionescu IG, Skowronski DM, Sauvageau C, Chuang E, Ouakki M, Kim S, De Serres G

BNT162b2 Effectiveness Against Delta and Omicron Variants of Severe Acute Respiratory Syndrome Coronavirus 2 in Adolescents Aged 12-17 Years, by Dosing Interval and Duration

Journal Article

J Infect Dis, 227 (9), 2023.

Abstract | Links:

Chambers C, Deeks SL, Sutradhar R, Cox J, de Pokomandy A, Grennan T, Hart TA, Lambert G, Moore DM, Grace D, Grewal R, Jollimore J, Lachowsky N, Nisenbaum R, Ogilvie G, Sauvageau C, Tan DHS, Coutlée F, Burchell AN

Vaccine Effectiveness Against 12-Month Incident and Persistent Anal Human Papillomavirus Infection Among Gay, Bisexual, and Other Men Who Have Sex With Men

Journal Article

J Infect Dis, 228 (1), 2023.

Abstract | Links:

Noiseux AS, Oliel G, Perrault-Sullivan G, Sauvageau S

Incidence et gravité du syndrome inflammatoire multisystémique de l'enfant au cours de la vague Omicron: revue rapide de la littérature

Book

Institut national de santé publique du Québec, Montréal, QC, 2023.

| Links:

157 entries « ‹ 1 of 16 › »
Signaler des ajouts ou des modifications

Active projects

  • Analyser les effets de la pandémie de COVID-19 sur l'utilisation communautaire des antibiotiques en fonction de la multimorbidité et rechercher des opportunités d'intervention contre l'antibioresistance, from 2023-05-29 to 2025-05-31
  • Durée de l'efficacité d'un calendrier de vaccination à deux doses contre les VPH et la plus-value d'une dose de rappel : diffusion des résultats clés de l'étude ICI-VPH pour soutenir la prise de décision, from 2022-02-02 to 2026-03-31
  • HPV vaccination effectiveness in a Canadian setting, 12 years after implementation: are we on the road to eliminate cervical, from 2020-10-01 to 2024-09-30
  • Optimization of HPV vaccination and screening in Canada, considering opportunities provided by 1-dose vaccination: A mathematical modeling study, from 2023-04-01 to 2025-03-31
  • Optimizing HPV vaccination programs in Low- and Middle-Income Countries (LMIC) and High-Income Countries (HIC) to reduce inequalities and reach global elimination of cervical cancer: An integrated knowledge translation dynamic-modeling, from 2024-03-01 to 2025-02-28

Recently finished projects

  • Essai clinique visant à documenter l’immunogénicité d’une dose de GARDASILMD ou GARDASIL 9MD et l’effet d’une dose du vaccin GARDASIL 9MD ou CERVARIXMD administré 3 ans et plus après la première dose, from 2023-10-13 to 2024-06-30
Data provided by the Université Laval research projects registery